2058
96
88
87
86
77
76
76
75
71
69
63
55
53
47
42
40
38
37
36
36
33
31
31
30
27
26
26
25
22
20
19
15
13
13
13
11
11
11
9
9
9
9
8
8
8
7
6
6
6
6
6
5
5
5
5
5
5
4
4
4
4
4
4
4
4
3
3
3
3
3
3
3
3
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
6199
619
699
69
3229
322
LANCET RESP MED
Combined amivantamab, lazertinib, and bevacizumab in patients with EGFR-mutant advanced non-small-cell lung cancer with acquired resistance to a third-generation EGFR tyrosine-kinase inhibitor (ETOP 18-21 AMAZE-lung): a prospective, international, multicentre, single-arm, phase 2 trial
PDF的下载单位、IP信息已删除
(2025-6-4)
秋风
无极微光
DW
Enigma_GEB
Dean
学术文献互助
aaaa
清爽老九
Juvenilesy
xing_xing
极限001
打工人
中华大团团
冷酷冰巧
LYSM
何志明
aajhajkahna
整齐的慕卉
共产主义战士
Yrzyc
皖公网安备34019202002308
